Research Article

Utility of Neck Circumference for Identifying Metabolic Syndrome by Different Definitions in Chinese Subjects over 50 Years Old: A Community-Based Study

Table 4

Comparison of NC and WC for discriminating metabolic syndrome and its components.

Sensitivity (%)Specificity (%)PPV (%)NPV (%)

MenNC ≥ 38.5 cmWC ≥ 90 cmNC ≥ 38.5 cmWC ≥ 90 cmNC ≥ 38.5 cmWC ≥ 90 cmNC ≥ 38.5 cmWC ≥ 90 cm
 Hypertension50.7 (45.3–56.2)45.4 (40.4–50.9)64.7 (58.1–70.8)68.5 (62.1–74.5)67.6 (61.4–73.3)67.7 (61.2–73.7)47.5 (41.9–53.1)46.4 (41.0–51.8)
 Hypertriglyceridemia56.1 (50.5–61.6)48.9 (43.3–54.4)70.6 (64.5–76.2)72.2 (66.2–77.7)71.1 (65.1–76.7)69.5 (63.0–75.4)55.4 (49.7–60.9)52.2 (46.8–57.6)
 Low HDL-C69.3 (58.6–78.7)63.6 (52.7–73.6)60.1 (55.6–84.5)64.7 (60.2–68.9)24.1 (19.0–29.9)24.8 (19.3–30.9)91.5 (87.8–94.3)90.7 (87.1–93.5)
 Hyperglycemia56.1 (48.3–63.6)52.0 (44.3–59.7)60.6 (55.6–65.4)65.7 (60.7–70.3)38.3 (32.3–44.7)39.8 (33.4–46.5)75.9 (70.8–80.6)75.8 (70.9–80.2)
 MS (ATP III)72.3 (65.3–78.5)76.4 (69.8–82.3)69.6 (64.7–74.2)78.8 (74.4–82.8)54.5 (48.2–60.8)64.6 (58.0–70.8)83.2 (78.6–87.2)86.9 (82.8–90.3)
WomenNC ≥ 33.4 cmWC ≥ 80 cmNC ≥ 33.4 cmWC ≥ 80 cmNC ≥ 33.4 cmWC ≥ 80 cmNC ≥ 33.4 cmWC ≥ 80 cm
 Hypertension68.1 (64.3–71.8)80.7 (77.4–83.8)51.8 (45.8–57.7)36.0 (30.4–41.9)75.3 (71.5–78.8)73.2 (69.7–76.5)42.9 (37.6–48.3)46.4 (39.7–53.2)
 Hypertriglyceridemia70.7 (66.6–74.6)83.3 (79.9–86.4)50.3 (45.1–55.4)35.3 (30.5–40.4)66.0 (61.9–69.9)63.8 (60.0–67.4)55.7 (50.2–61.0)60.8 (54.0–67.3)
 Low HDL-C75.2 (69.5–80.3)86.6 (81.9–90.5)43.6 (39.7–47.5)29.1 (25.6–32.8)35.2 (31.3–39.4)33.3 (29.8–37.0)81.2 (76.6–85.1)84.2 (78.7–88.8)
 Hyperglycemia77.1 (72.2–81.6)87.5 (83.4–90.9)46.9 (42.7–51.0)31.4 (27.6–35.4)45.3 (41.1–49.5)42.1 (38.3–45.9)78.3 (73.5–82.5)81.5 (75.8–86.4)
 MS (ATP III)79.0 (75.1–82.4)94.4 (92.1–96.3)59.8 (54.8–64.6)48.5 (43.5–53.5)71.2 (67.2–74.9)69.8 (66.2–73.2)69.3 (64.1–74.1)87.4 (82.3–91.5)

NC: neck circumference; WC: waist circumference; PPV: positive predictive value; NPV: negative predictive value; HDL-C: high-density lipoprotein cholesterol; ATP III: Adult Treatment Panel III.